新兴的自然疗法用于治疗炎症性肠病
Monika Joshi1, Manju Pandey1, Ravi Shankar2
1Sri Ramswaroop Memorial University, Institute of Pharmacy, Barabanki, UP-225003, India.
Current pharmaceutical biotechnology
|May 8, 2024
概括
天然药物对治疗炎症性肠病 (IBD),包括克罗恩病和性结肠炎有前途. 需要进一步的研究来证实这些植物性治疗的安全性和有效性.
科学领域:
- 胃肠病学和肝病学
- 自然产品化学 自然产品化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 炎症性肠病 (IBD),包括克罗恩病 (CD) 和性结肠炎 (UC),是一种慢性消化系统炎症.
- 目前的治疗方法,如皮质类固醇和生物药物提供有限的长期缓解,并携带显著的副作用 (例如,毒性,不孕症).
研究的目的:
- 审查IBD治疗的自然医学选择.
- 为了确定具有针对IBD潜在治疗活性的植物.
- 突出需要进一步研究IBD的自然疗法.
主要方法:
- 对已报告对IBD有活性的植物进行文献分析.
- 确定用于IBD治疗的关键植物物种.
主要成果:
- 一些植物,包括大麻树,,,Boswellia serrata,Withania somnifera,Curcuma longa和Triticum aestivum,显示有前途的活动.
- 这些天然药物正在被探索,作为传统疗法的潜在更安全,更具成本效益的替代品.
结论:
- 天然药物是IBD管理的有希望的途径,因为副作用较少,成本较低.
- 广泛的临床前和临床研究对于验证这些植物性治疗的安全性,疗效和作用机制至关重要.
- 监管框架对于这些自然疗法的最终商业化至关重要.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
126
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
126
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
158
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
158
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
115
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
115
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
131
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
131
Drugs for Treatment of Ulcerative Colitis in IBD
136
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
136


